Related Experiment Video
Updated: May 14, 2026

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats
Published on: March 23, 2018
Antithrombin activity and outcomes in patients undergoing cardiac surgery with cardiopulmonary bypass
Vicente Muedra1, Domingo Barettino, Pilar D'Ocón
1Departamento de Anestesiología, Reanimación y Terapia del Dolor, Hospital Universitario La Ribera, Alzira-Valencia, Spain. vmuedra@hospital-ribera.com
Insights
Post-cardiopulmonary bypass (CPB) antithrombin (AT) activity significantly decreases after cardiac surgery. Lower AT activity is linked to increased complications, highlighting its role in patient outcomes.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Hematology
Background:
- Antithrombin (AT) activity is crucial for anticoagulation during cardiopulmonary bypass (CPB).
- Previous studies showed limited correlation between baseline parameters and post-CPB AT activity.
- Understanding factors influencing post-CPB AT is vital for optimizing patient safety.
Purpose of the Study:
- To investigate the relationship between patient characteristics, CPB, and post-CPB AT activity in a larger cohort.
- To identify predictors of decreased post-CPB AT activity.
- To explore the association between post-CPB AT activity and clinical outcomes.
Main Methods:
- Prospective analysis of 250 patients undergoing elective cardiac surgery with CPB.
- Collection of sociodemographic, pre-CPB clinical data, and pre/post-CPB AT activity.
- General linear models, univariate, and multivariate analyses were employed.
Main Results:
- A significant decrease in post-CPB AT activity was observed (95.6% to 64.6%).
- Age was inversely correlated with post-CPB AT activity (approx. 1% decrease per 3 years).
- Univariate analysis indicated inverse relationships between post-CPB AT activity and complications, but multivariate analysis lacked statistical significance.
Conclusions:
- Post-CPB AT activity significantly declines following cardiac surgery.
- Patient age is a key factor associated with reduced post-CPB AT activity.
- Low post-CPB AT activity may influence surgical outcomes, warranting further investigation.
Abstract:
We recently reported prospective results from a cohort of patients scheduled for elective cardiac surgery with cardiopulmonary bypass (CPB) in which most baseline clinical parameters of patients and surgery outcomes failed to demonstrate relationships with post-CPB antithrombin (AT) activity. In this extension study, a larger sample size (250 patients) was analyzed following general linear models. Patients' sociodemographic and pre-CPB clinical data as well as pre/post-CPB AT activity and outcomes were collected. There was a significant decrease of post-CPB AT activity (95.6 ± 13.7-64.6 ± 12.1%; P < 0.001). Univariate and multivariate analyses revealed that a decrease of approximately 1% post-CPB AT activity may be expected per 3 years increase in patient's age. Univariate analysis showed that post-CBP AT activity was inversely related to the need for transfusions, acute renal failure and occurrence of any complication (re-intervention, low cardiac output, arrhythmia, lung dysfunction, stroke, acute renal failure, mesenteric ischemia and re-hospitalization; P < 0.05). Multivariate analysis adjusted for age and pre-CPB AT did not show statistical significance. Odds ratio (OR) less than 1 was observed in most outcomes (0.8 on average), which suggested a reduction of the probability for an increase of 10% in post-CBP AT. Our results confirm the role of low postsurgery AT activity influencing outcomes in patients undergoing CPB.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...